Kornimate/medical-research-clean huggingface dataset:
first-in-human study of interferon-y pet imaging to assess response to immunotherapy

Conditions: Non Small Cell Lung Cancer

Summary: the goal of this clinical trial is to investigate the use of \[89zr\]zr-dfo-emapalumab as an ifn-γ pet imaging agent to detect lesions and response to therapy among treatment-naïve non-small cell lung cancer (nsclc) patients. pet scans following the imaging agent will be completed prior to and about 30 days after starting immunotherapy.

participants will be enrolled into the clinical trial once confirmed eligible. screening activities include, standard of care blood work, medical history and a physical exam. -within 14 days of starting immunotherapy, participants will complete pet scans 1-2 hours post-tracer administration, again on the day following tracer administration, and 3-5 days after the tracer administration. this sequence may be repeated 25-45 days after the start of treatment with immunotherapy for a total of two tracer injections and up to six pet scans.

Eligibility criteria:
inclusion * prior histologic or cytologic diagnosis of non-small cell lung cancer. * fdg pet done within 2 months of the baseline imaging, as part of standard-of-care. * measurable disease by recist 1.1 with at least one lesion of at least 2 cm in a region of the body that can be imaged by pet (e.g.,outside of the liver) * must be able to lie still for the tests. their girth and weight must be suitable to enter the gantry, which varies per tomograph. * must be \>18 years old. * patients must sign an informed consent indicating that they are aware of the investigational nature of this study, in keeping with the policies of the cancer center. * physical exam, cbc and multiphasic (including electrolytes, bun, creatinine, total bilirubin, ast, and alt) must be done within 28 days prior to pet imaging exclusion * no prior immunotherapy for current stage of nsclc (non small cell lung cancer). immunotherapy in neoadjuvant or adjuvant setting and have recurrence at least 12 months following completion of immunotherapy are eligible after discussion with the principle investigator. * pregnant or breast feeding individuals.
thromboembolic complications related to asparaginase in children with acute lymphoblastic leukemia (all) treated according to nopho all 2008

Conditions: Thromboembolism; Acute Lymphoblastic Leukemia

Summary: the study will examine the prevalence of venous thromboembolism in children with acute lymphoblastic leukaemia treated in accordance with nopho all-2008. the investigators will prospectively study clinical symptomatic thromboses, asymptomatic central line-associated thromboses, and infections.


Eligibility criteria:
inclusion criteria: * acute lymphoblastic leukaemia, * age 1 year to 16 years old, * central line, * protocol nopho all 2008. exclusion criteria: * refusal of participation, * treated according to protocol other than nopho all 2008.

Keywords: asparaginase thrombosis all central line
a pilot study of a non-invasive neuromodulation device for treatment of parkinson's disease

Conditions: Parkinson's Disease

Summary: this is a single-center, open label study evaluating the acute effect of caloric vestibular stimulation on updrs motor scores in parkinson's disease patients.


Eligibility criteria:
inclusion criteria: * patient should have a updrs motor score of 14 (off medication) or higher (mild to moderate) * patient should have a hoehn \& yahr staging of 1 to 3 (mild to moderate) * patient must be an adult (18 years of age or older) exclusion criteria: * women who are pregnant or nursing * have a history of significant cardiovascular disease (no pacemakers) * have a history of unstable mood disorder or unstable anxiety disorder or psychosis * use a hearing aid * have a cochlear implant * have been diagnosed with neurological disease other than parkinson's disease. no atypical parkinsonism. * have a diagnosed vestibular dysfunction * abuse alcohol or other drugs * have had eye surgery within the previous three months or ear surgery within the previous six months * have active ear infections or a perforated tympanic membrane * have participated in another clinical trial within the last 30 days or are currently enrolled in another clinical trial

Keywords: parkinson's disease
omega-3 hydrogel and prevention of oral mucositis

Conditions: Mucositis Oral

Summary: oral mucositis (om) is recognized as one of the most frequent debilitating sequela encountered by head and neck cancer (hnc) patients treated by radiotherapy. the objective of the study is to assess primarily the effect of topical oral omega-3 hydrogel in prevention of radiation-induced oral mucositis and secondarily, to test the effect of topical oral omega-3 hydrogel on oral microbiome.


Eligibility criteria:
inclusion criteria: 1. patients who are going to receive radiotherapy as a treatment of head and neck cancer either as postoperative (adjuvant) therapy or definitive therapy. 2. patients whose radiotherapy treatment planned dose is 50 gy or above 3. males and females with an age not less than 18 years 4. patients receiving radiotherapy alone or receiving concomitant cisplatin (or carboplatin) with radiotherapy. exclusion criteria: 1. patients under anticoagulants such as warfarin, heparin, or aspirin. 2. patients suffering from any uncontrolled systemic diseases (such as diabetes, cardiovascular, liver disorder, renal dysfunction) 3. patients with findings of any physical or mental abnormality which would interfere with or be affected by the study procedure.
a study to evaluate the efficacy and safety of renexin cr in patients with acute non-cardioembolic ischemic stroke

Conditions: Ischemic Stroke

Summary: a study to evaluate the efficacy and safety of renexin cr in patients with acute non-cardioembolic ischemic stroke


Eligibility criteria:
inclusion criteria: 1) patients identified as acute non-cardioembolic ischemic stroke on mri within 72 hours of onset of symptoms of cerebral infarction. exclusion criteria: 1. patients with active cancer; vascular malformation, abscess, or other major non-ischemic brain disease (e.g., multiple sclerosis). 2. with a modified rankin score (mrs) of 3 or higher before onset. 3. underwent intravenous thrombolytic therapy (intravenous rtpa) or mechanical thrombectomy within 24 hours of the screening visit. 4. history of hypersensitivity to ip or components 5. not suitable for aspirin administration at the discretion of the investigator
comparison of the efficacy of entecavir and tenofovir monotherapy for the treatment of nucleos(t)ide-naïve patients with chronic hepatitis b in korea

Conditions: Chronic Hepatitis B

Summary: chronic hepatitis b virus infection is an important cause of morbidity and mortality. tenofovir disoproxil fumarate and entecavir were licensed for the treatment of hepatitis b virus infection. in this study, the investigators will try to make comparison between entecavir and tenofovir and investigate the efficacy.


Eligibility criteria:
inclusion criteria: * 18 \< age \< 70 * hbv dna \> 100,000 copies/ml and increased alt over 2 times compared with normal range if hbsag (+), hbeag (+) * hbv dna \> 10,000 copies/ml and increased alt compared with normal range if hbsag (+), hbeag (-) exclusion criteria: * with hcv or other liver disease * with kidney disease * decompensated liver cirrhosis * with hepatocellular carcinoma * refuse this clinical trials

Keywords: entecair tenofovir
thymosin-alpha 1 for adjuvant treatment after radical resection of high-risk stage ii and iii colorectal cancer

Conditions: Stage II Colorectal Cancer; Stage III Colorectal Cancer

Summary: for high-risk stage ii and stage iii colorectal cancer, even after radical resection and postoperative adjuvant chemo/radiotherapy, 30-40% of patients will still have recurrence and metastasis. thymosin-alpha 1 is believed to improve immunity and may help promote tumor immunity to reduce the incidence of recurrence and metastasis. this study hopes to verify the effecacy and safety of thymosin-alpha 1 for adjuvant treatment of high-risk stage ii and stage iii colorectal cancer after radical resection.

patients with pathological high-risk stage ii and stage iii colorectal cancer after radical resection were randomly allocated to receive thymosin-alpha 1 twice a week for 6 months (experimental group) or not (control group) in a 1:1 ratio. at the same time, all patients will receive chemo/radiotherapy according to the chinese standards for diagnosis and treatment of colorectal cancer. the primary endpoint is 3-year dfs rate.

Eligibility criteria:
inclusion criteria: * colorectal cancer receiving radical resection * pathologically diagnosed with high-risk stage ii or stage iii * eastern cooperative oncology group performance status of 0-2 * adequate hepatic, renal, and hematologic function exclusion criteria: * had previously taken any immune-promoting drugs * pregnancy or lactation

Keywords: colorectal cancer adjuvant treatment thymosin-alpha 1 disease-free survival
a safety and efficacy study evaluating ctx131 in adult subjects with relapsed or refractory solid tumors

Conditions: Clear Cell Renal Cell Carcinoma; Cervical Carcinoma; Esophageal Carcinoma; Pancreatic Adenocarcinoma; Malignant Pleural Mesothelioma

Summary: this is an open-label, multicenter, phase 1/2 study evaluating the safety and efficacy of ctx131™ in subjects with relapsed or refractory solid tumors.

an open-label, multi-center phase 1/2 study of ctx131 in subjects with relapsed/refractory solid tumors. ctx131 is an is allogeneic cd70- directed chimeric antigen receptor (car) t cell immunotherapy comprised of allogeneic t cells that are genetically modified ex vivo using crispr-cas9 (clustered regularly interspaced short palindromic repeats/ crispr associated protein 9) gene editing components (single guide rna and cas9 nuclease).

Eligibility criteria:
key inclusion criteria: 1. age ≥18 years. 2. unresectable or metastatic, relapsed/refractory, clear cell renal cell carcinoma, cervical carcinoma, pancreatic adenocarcinoma, esophageal carcinoma, and malignant pleural mesothelioma. 3. eastern cooperative oncology group performance status 0 or 1. 4. adequate renal, liver, cardiac and pulmonary organ function. 5. female subjects of childbearing potential and male subjects must agree to use acceptable method(s) of contraception from enrollment through at least 12 months after ctx131 infusion. key exclusion criteria: 1. prior treatment with anti-cd70 targeting agents 2. history of certain central nervous system (cns), cardiac or pulmonary conditions. 3. presence of uncontrolled bacterial, viral, or fungal infection. 4. active hiv, hepatitis b virus or hepatitis c virus infection. 5. primary immunodeficiency disorder or active autoimmune disease requiring steroids and/or other immunosuppressive therapy. 6. women who are pregnant or breastfeeding.

Keywords: car-t allogeneic carcinoma
feasibility study of multidimensional rehabilitation in the metaverse

Conditions: Colorectal Neoplasms

Summary: the investigators evaluated and optimized the metaverse multi-dimensional rehabilitation platform based on the use of the metaverse multi-dimensional rehabilitation platform by colorectal cancer survivors and their families, and finally launched the metaverse multi-dimensional rehabilitation platform.

the investigatorse intend to invite colorectal cancer survivors and their families to use the metaverse multi-dimensional rehabilitation platform. interviews with users, user experience optimization of the metaverse multi-dimensional rehabilitation platform, and then evaluation of the platform through system usability evaluation. gain insight into the experience of colorectal cancer survivors using the metaverse multi-dimensional rehabilitation platform, and understand their opinions and suggestions to explore the usability of the metaverse multi-dimensional rehabilitation platform.

Eligibility criteria:
inclusion criteria: * patients undergoing adjuvant therapy after radical colorectal cancer resection; age over 18 years old, under 65 years old, non-pregnant; volunteering to participate in the research of this topic; mobile phones are available exclusion criteria: * patients with multiple cancers; have special dietary needs.

Keywords: metaverse multi-dimensional rehabilitation platform
pins stimulator system for deep brain stimulation to treat obesity

Conditions: Obesity

Summary: the purpose of this clinical study is to verify the long term effecacy and safety of a bilateral deep brain stimulation (dbs) produced by beijing pins medical co., ltd. as a treatment option for patients with obesity.


Eligibility criteria:
inclusion criteria: 1. subject is aged 18 to 65. 2. body mass index \[bmi\] \>40 kg/m2. exclusion criteria: 1. medical contraindications for general anesthesia, craniotomy, or dbs surgery 2. evidence of neurological disorders, e.g., multiple sclerosis, parkinson's disease and ischemic stroke, or severe brain atrophy or the presence of subdural hygromas or subdural hematomas. 3. participate in other clinical trial; 4. has a life expectancy of \< 1 year. 5. the investigator and/or enrollment review committee, would preclude participation in the study.
return of function and external rotation post proximal humerus fracture fixation with neutral rotation brace

Conditions: Proximal Humeral Fracture

Summary: research question: do patients using a neutral rotation brace post surgery have improved functional outcome and external rotation of the shoulder compared to current best practice using a polysling holding the proximal humerus in internal rotation? primary objectives: to compare post-operative functional outcome scores obtained at 6 weeks, 9 weeks, 3 months and 1 year. (scores at 6 weeks and 3 months in clinical review and postal scores at 9 weeks and 1 year) between patients held in neutral versus current standard rotation. these will be compared to scores taken pre-operatively. benefits: there may be no extra benefits to patients from this trial however the results from the trial will help improve treatment for future patients at this hospital, and others across the country. risks/disadvantages: the operation is the same in both groups studied, the study is investigating the use of the two different slings. the post-operative treatment is also the same, and all patients on the trial will receive the same amount of physiotherapy. it isn't anticipated that there will be any additional risk from this trial.


Eligibility criteria:
inclusion criteria: * proximal humeral fractures requiring operative intervention with extramedullary plate fixation (i.e. fractures displaced by 1cm and/or angulated by 45 degrees or more) * age over 18 years of age * patient able to give informed consent exclusion criteria: * patients having intra-operative findings to complete pectoralis major rupture or if operative exposure requires complete pectoralis major tenotomy. (these patients need to be held in internal rotation with a standard polysling to allow healing of the pectoralis major tendon) * patients under 18 years of age * patients unable to give informed consent

Keywords: proximal humeral fracture shoulder orthopaedics neutral rotation brace polysling
prevention of relapses in proteinase 3 (pr3)-anti-neutrophil cytoplasmic antibodies (anca)-associated vasculitis

Conditions: Vasculitis

Summary: treatment of patients with pr3-anca-associated vasculitis consists of two phases: remission induction with highly effective, but also relatively toxic, drugs and, secondly, after remission is achieved, maintenance therapy with less toxic drugs. currently, remission-maintenance therapy with azathioprine is stopped after approximately 18 months. however, the optimal duration of azathioprine maintenance therapy is unknown. the investigators have found that patients with pr3-anca-associated vasculitis who remain cytoplasmic anti-neutrophil cytoplasmic autoantibody (c-anca) positive after induction of remission have an increased risk to experience relapse of disease. therefore they will test whether relapse risk in these patients can be reduced by extending maintenance therapy at the cost of acceptable therapy related toxicity. after induction of stable remission, anca will be measured by immunofluorescence (iif). c-anca positive patients will be randomized for either standard therapy with azathioprine (until 18 months after diagnosis), or longterm azathioprine maintenance therapy (until 48 months after diagnosis).

treatment of patients with pr3-anca-associated vasculitis consists of two phases: remission induction with highly effective, but also relatively toxic, drugs and, secondly, after remission is achieved, maintenance therapy with less toxic drugs. currently, remission-maintenance therapy with azathioprine is stopped after approximately 18 months. however, the optimal duration of azathioprine maintenance therapy is unknown. the investigators have found that patients with pr3-anca-associated vasculitis who remain c-anca positive after induction of remission have an increased risk to experience relapse of disease (mc slot et al. arthritis rheum. 2004 15;51(2):269-73). therefore they will test whether relapse risk in these patients can be reduced by extending maintenance therapy at the cost of acceptable therapy related toxicity. after induction of stable remission, anca will be measured by iif. c-anca positive patients will be randomized for either standard therapy with azathioprine (until 18 months after diagnosis), or longterm azathioprine maintenance therapy (until 48 months after diagnosis).

Eligibility criteria:
inclusion criteria: * newly diagnosed anca-associated vasculitis * pr3-anca antibodies present * indication for treatment with cyclophosphamide and prednisolone exclusion criteria: * intolerance or allergy to azathioprine

Keywords: wegener's granulomatosis, anca, vasculitis, proteinase 3 anca-associated vasculitis anca
modified extension study to the sumit trial: evaluation of long term therapy with percutaneous tibial nerve stimulation (ptns) for overactive bladder symptoms

Conditions: Urinary Bladder, Overactive

Summary: this is a modified extension study to the sumit protocol upc082008 (nct00534521) to observe and evaluate long term therapy with ptns on overactive bladder symptoms. subjects must have completed the 12 weekly treatments of the original protocol, the 13 week follow up assessment, be randomized to the ptns arm, and be considered a positive responder with moderate or marked improvement in the sumit trial to be enrolled in this study. all consenting responders will continue with active ptns therapy at an initially prescribed protocol for approximately 3 months followed by individualized symptom-based frequency of visits as determined by the subject along with their treating clinician, for up to a total of 33 months post initial 12-week therapy for a total of 3 years.


Eligibility criteria:
inclusion criteria: * subjects who signed the informed consent and were eligible to participate in the original sumit trial * subjects who were randomized and treated with the active ptns therapy during their participation in the original sumit trial * subject must be a positive responder from initial 12 weekly treatments as prescribed in original sumit trial - 13 week gra questionnaire must indicate "moderately" or "markedly improved" on question #1 of gra * subjects must not have started any antimuscarinics treatment since completion of original sumit trial * subjects must not have started any urologic botox treatment since completion of original sumit trial * subjects must remain off all antimuscarinics throughout participation in trial * subjects must initiate ptns maintenance therapy within 2 weeks of their last ptns treatment as part of sumit protocol upc082008 * capable of giving informed consent * capable and willing to follow all study-related procedures for up to 33 months for a total participation of 3 years exclusion criteria: * pregnant as confirmed by urine pregnancy test, or plans to become pregnant during the study period * subjects who were not able or willing to follow original sumit trial study schedule

Keywords: urgent pc overactive bladder sumit trial overactive urinary bladder
qigong for post acute sequelae of covid-19 infection

Conditions: Long COVID

Summary: the purpose of this study is to conduct a pilot feasibility study of external qigong on health-related quality of life in individuals with prolonged symptoms following covid-19 infection.

the purpose of this study is to determine whether external qigong, a traditional chinese medicine healing practice, improves quality of life and symptoms for individuals with prolonged symptoms following a covid-19 infection (sometimes called "long covid"). the study involves completing questionnaires and participating in 6 weekly in person small group qigong sessions with an experienced qigong practitioner. participants will be randomized to participate in either an immediate or waitlist control group that will receive the qigong sessions starting 8 weeks later. participants will complete 3 sets of questionnaires, each about 8 weeks apart and an interview about their experiences with qigong after completing the 6 sessions.

Eligibility criteria:
inclusion criteria: 1. english-speaking adults age 18 or greater 2. history of a covid-19 infection with lingering symptoms lasting longer than 12 weeks 3. willing and able to access the internet to complete questionnaires 4. willing and able to travel to the qigong sessions to participate in person in sacramento, ca. exclusion criteria: 1. lung scarring secondary to covid-19 infection as evidenced by signs of parenchymal lung damage on imaging or fvc \< 80% (any patient with post covid-related shortness of breath must have pfts to be considered for enrollment). 2. dementia 3. any other condition that makes it difficult for the individual to complete questionnaires or attend the qigong sessions.

Keywords: qigong
isotopic imaging for prodromal alzheimer's disease

Conditions: Alzheimer Disease

Summary: the primary objective of this study is to characterize cerebral metabolism modifications using 18f-fdg pet technology and perfusion with 99mtc-ecd spect in patients with prodromal alzheimer's disease drawn from a high risk population. we also compare pet and spect imaging within this framework, and search for optimal diagnostic thresholds.


Eligibility criteria:
inclusion criteria for the group with memory problems: * patient consulting for memory problems * caucasian * memory complaint is validated by a clinical evaluation * cognitive performance is sufficiently well preserved so that a diagnostic of dementia cannot be made (according to the dsm-iv-r and nincds-adrda criteria) at the time of inclusion * the patient speaks french * presence of an informant * accepts to sign consent inclusion criteria for the group without memory problems (reference population): * at least four years of formal education * patient consulting for memory problems * memory problem reported by the patient is not validated by the consultation, nor by the battery of tests specified during screening * presence of an informant * clinical dementia rating (cdr) = 0 * accepts to sign consent exclusion criteria: * instrumental activities of daily living (iadl): at least two items \> 1 * anticholinesterasic treatments and/or memantin before study inclusion * major depressive syndrome, according to the global depressive scale * known neurodegenerative disease or general disease or major physical problems that could interfere with cognitive functioning and testing * pathology that might lead to death in the short term (evolving cancer, non stable cardiopathy, hepatic, renal or respiratory insufficiency) * contra-indications for mri, pet or spect scans * not affiliated with a social security regimen